Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial
Authors:
Open Access
- 1 April 2016
- journal article
- Published by Elsevier in Translational Oncology
- Vol. 9 (2) , 108-113
Abstract
No abstract availableKeywords
Funding Information
- EpicentRx, Inc.
This publication has 33 references indexed in Scilit:
- Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agentsOncoTargets and Therapy, 2011
- The Evolving Role of Radiation Therapy in the Management of Malignant MelanomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Prognostic factors for survival in melanoma patients with brain metastasesCancer, 2010
- Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanomaCancer, 2008
- Review: Implications of In Vitro Research on the Effect of Radiotherapy and Chemotherapy Under Hypoxic ConditionsThe Oncologist, 2007
- Temozolomide plus thalidomide in patients with brain metastases from melanomaCancer, 2005
- Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II StudyJournal of Clinical Oncology, 2004
- Determinants of Outcome in Melanoma Patients With Cerebral MetastasesJournal of Clinical Oncology, 2004
- Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working GroupJournal of Cancer Research and Clinical Oncology, 2002
- Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanomaJournal of Neurosurgery, 1998